A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy.

H. R. Mundy; S. J. Jones; J. C. Hobart; M. G. Hanna; P. J. Lee

doi:10.1212/01.wnl.0000079460.21925.d3

A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy.

H. R. Mundy^*, S. J. Jones, J. C. Hobart, M. G. Hanna, P. J. Lee

^*Corresponding author for this work

Peninsula Medical School

University College London

Research output: Contribution to journal › Article › peer-review

Abstract

Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated. There were no significant improvements with therapy. The authors do not confirm previous anecdotal reports of dramatic improvement with modified cobratoxin.

Original language	English
Pages (from-to)	528-530
Number of pages	0
Journal	Neurology
Volume	61
Issue number	4
DOIs	https://doi.org/10.1212/01.wnl.0000079460.21925.d3
Publication status	Published - 26 Aug 2003

Keywords

Adrenoleukodystrophy
Adult
Aged
Cobra Neurotoxin Proteins
Double-Blind Method
Evoked Potentials
Female
Humans
Male
Middle Aged
Severity of Illness Index
Treatment Failure

Access to Document

10.1212/01.wnl.0000079460.21925.d3

Cite this

@article{32d05140ecad40bdb11b20e3e795813f,

title = "A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy.",

abstract = "Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated. There were no significant improvements with therapy. The authors do not confirm previous anecdotal reports of dramatic improvement with modified cobratoxin.",

keywords = "Adrenoleukodystrophy, Adult, Aged, Cobra Neurotoxin Proteins, Double-Blind Method, Evoked Potentials, Female, Humans, Male, Middle Aged, Severity of Illness Index, Treatment Failure",

author = "Mundy, {H. R.} and Jones, {S. J.} and Hobart, {J. C.} and Hanna, {M. G.} and Lee, {P. J.}",

year = "2003",

month = aug,

day = "26",

doi = "10.1212/01.wnl.0000079460.21925.d3",

language = "English",

volume = "61",

pages = "528--530",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy.

AU - Mundy, H. R.

AU - Jones, S. J.

AU - Hobart, J. C.

AU - Hanna, M. G.

AU - Lee, P. J.

PY - 2003/8/26

Y1 - 2003/8/26

N2 - Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated. There were no significant improvements with therapy. The authors do not confirm previous anecdotal reports of dramatic improvement with modified cobratoxin.

AB - Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated. There were no significant improvements with therapy. The authors do not confirm previous anecdotal reports of dramatic improvement with modified cobratoxin.

KW - Adrenoleukodystrophy

KW - Adult

KW - Aged

KW - Cobra Neurotoxin Proteins

KW - Double-Blind Method

KW - Evoked Potentials

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Severity of Illness Index

KW - Treatment Failure

U2 - 10.1212/01.wnl.0000079460.21925.d3

DO - 10.1212/01.wnl.0000079460.21925.d3

M3 - Article

SN - 0028-3878

VL - 61

SP - 528

EP - 530

JO - Neurology

JF - Neurology

IS - 4

ER -

A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy.

Abstract

Keywords

Access to Document

Fingerprint

Cite this